Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Link to XBRL Interactive Data 30 June 2018

September 3, 2018 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

Post navigation

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Related Posts

Prana Provides Clinical Trials Update

July 17, 2013

ABC Radio Jon Faine Program features Prana IMAGINE trial for Alzheimer’s disease

July 17, 2013

Prana Biotechnology Investor Presentation

June 27, 2018

Recent Posts

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065